Skip to Content

Eurofins Scientific SE ERF

Morningstar Rating
€56.64 −0.86 (1.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Eurofins Earnings: Revenue Growth In Line; Shares Modestly Undervalued

Narrow-moat Eurofins’ first-quarter results were decent, with reported revenue growing 5% year on year despite a 1% foreign-exchange headwind and one less public working day. This is in line with our expectations and represents good progress on the company’s objective of approximately EUR 7.125 billion revenue for 2024. We maintain our fair value estimate of EUR 72 per share with the view that margins will improve over the next two to three years. Shares are currently trading at about a 20% discount to this, and we view shares as modestly undervalued.

Price vs Fair Value

ERF is trading within a range we consider fairly valued.
Price
€61.60
Fair Value
€25.00
Uncertainty
Medium
1-Star Price
€46.40
5-Star Price
€24.30
Economic Moat
Zvkpdbn
Capital Allocation
Rvpnztq

Bulls Say, Bears Say

Bulls

Eurofins has consistently delivered organic growth greater than global economic growth, a sign of consistent share gains despite high market competition and fragmentation.

Bears

Operating margins have fallen recently due to wage inflation in Europe, and it remains to be seen to what extent Eurofins can increase pricing to improve margins.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ERF is a good fit for your portfolio.

Trading Information

Previous Close Price
€57.50
Day Range
€55.7057.84
52-Week Range
€44.8365.24
Bid/Ask
€56.60 / €56.80
Market Cap
€10.93 Bil
Volume/Avg
413,821 / 348,466

Key Statistics

Price/Earnings (Normalized)
19.63
Price/Sales
1.72
Dividend Yield (Trailing)
1.77%
Dividend Yield (Forward)
1.77%
Total Yield
2.20%

Company Profile

Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 900 laboratories in 61 countries. Its revenue from Europe, North America, and the Rest of the World contribute approximately 50%, 40%, and 10% of total revenue respectively. Its areas of business activity are food, feed, and environmental testing ("Life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
61,798

Competitors

Valuation

Metric
ERF
BVI
ITRK
Price/Earnings (Normalized)
19.6319.5021.37
Price/Book Value
2.676.496.02
Price/Sales
1.722.162.41
Price/Cash Flow
11.0814.7915.28
Price/Earnings
ERF
BVI
ITRK

Financial Strength

Metric
ERF
BVI
ITRK
Quick Ratio
1.341.671.02
Current Ratio
1.451.671.09
Interest Coverage
4.188.4010.40
Quick Ratio
ERF
BVI
ITRK

Profitability

Metric
ERF
BVI
ITRK
Return on Assets (Normalized)
5.44%8.25%10.16%
Return on Equity (Normalized)
13.87%31.39%28.28%
Return on Invested Capital (Normalized)
7.66%12.79%14.92%
Return on Assets
ERF
BVI
ITRK
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncMndnvnjjvYnwh$209.3 Bil
DHR
Danaher CorpKvhfjrmnMmhvyc$182.1 Bil
IQV
IQVIA Holdings IncMnjvhrdgGqlpmt$42.8 Bil
IDXX
IDEXX Laboratories IncBsdxyhxxqHwlqxc$41.5 Bil
A
Agilent Technologies IncFgqwwmqnbRsky$40.4 Bil
MTD
Mettler-Toledo International IncQkznzqpscQnjbwxk$26.5 Bil
ICLR
Icon PLCYgldslyvRgzcs$24.8 Bil
ILMN
Illumina IncTpzxtbhsxTmbwlf$19.5 Bil
WAT
Waters CorpRqccdzwgRhcpm$18.5 Bil
LH
Laboratory Corp of America HoldingsRtdjgfvyyDsqzry$16.7 Bil

Sponsor Center